News
SONN
4.460
+3.00%
0.130
Weekly Report: what happened at SONN last week (1028-1101)?
Weekly Report · 1d ago
Sonnet stock tumbles 22% in wake of proposed offering filing
Seeking Alpha · 10/28 16:45
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/28 16:30
BUZZ-U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake Shack
Reuters · 10/28 16:28
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views
Benzinga · 10/28 13:59
Sonnet Biotherapeutics Files To Sell Common Stock, Warrants; Terms Not Disclosed
Benzinga · 10/28 13:57
Sonnet BioTherapeutics files to sell common stock, warrants, no amount given
TipRanks · 10/28 13:05
Weekly Report: what happened at SONN last week (1021-1025)?
Weekly Report · 10/28 12:12
Weekly Report: what happened at SONN last week (1014-1018)?
Weekly Report · 10/21 12:06
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/17 16:30
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance
TipRanks · 10/17 13:17
Sonnet BioTherapeutics Regains Compliance With Nasdaq
Benzinga · 10/17 12:49
SONNET BIOTHERAPEUTICS INC. REGAINS COMPLIANCE WITH NASDAQ
Reuters · 10/17 12:45
Weekly Report: what happened at SONN last week (1007-1011)?
Weekly Report · 10/14 12:47
Sonnet Partners Alkem To Develop And Market SON-080 For Diabetic Peripheral Neuropathy In India
NASDAQ · 10/09 13:34
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
TipRanks · 10/09 13:17
Sonnet BioTherapeutics, Alkem enter licensing agreement for SON-080
TipRanks · 10/09 12:50
Sonnet BioTherapeutics Enters Licensing Agreement With Alkem Laboratories For Development And Commercialization Of SON-080 In India For Diabetic Peripheral Neuropathy
Benzinga · 10/09 12:45
SONNET BIOTHERAPEUTICS HOLDINGS INC - ENTITLED TO RECEIVE LOW DOUBLE-DIGIT ROYALTY ON NET SALES OF SON-080
Reuters · 10/09 12:45
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
Barchart · 10/09 07:45
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.